Значения термина noninvasive prenatal на английском

Background: Massively parallel sequencing has recently been used in noninvasive prenatal diagnosis.

Circulating fetal nucleated cells (CFNCs) have shown potential in noninvasive prenatal diagnostics.

It is an essential quality control component of noninvasive prenatal testing (NIPT) results.

Genetic evaluation consisted of noninvasive prenatal screening (NIPS) or amniocentesis.

Our strategy represents a generic approach for noninvasive prenatal testing for an array of autosomal recessive disorders.

The discovery of fetal mRNA transcripts in the maternal circulation holds great promise for noninvasive prenatal diagnosis.

The discovery of cell-free DNA molecules in maternal plasma has opened up numerous opportunities for noninvasive prenatal testing.

Recently, practices have begun integrating cell-free DNA-based noninvasive prenatal screening as a screening option for a variety of genetic conditions.

This high number of fetal cells is regarded as an advantage for the development of a noninvasive prenatal diagnostic test.

During pregnancy, the circulating fetal cells in maternal blood constitute a potential source for development of a noninvasive prenatal diagnosis.

We explored the use of massively parallel sequencing of maternal plasma DNA for the noninvasive prenatal assessment of the zygosities of twin pregnancies.

A total of 551 pregnancies with positive results for noninvasive prenatal testing (NIPT) using traditional karyotyping and chromosomal microarray analysis were analyzed.

Conclusions: Noninvasive prenatal determination of twin zygosity by maternal plasma DNA sequencing is feasible.

Noninvasive prenatal screening (NIPS) is revolutionizing prenatal screening as a result of its increased sensitivity, specificity.

Noninvasive prenatal detection of monogenic diseases based on cell-free DNA is hampered by challenges in obtaining a sufficient fraction and adequate quality of fetal DNA.